CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- 4 Open-market sale Chief R&D Officer sold 1,157 shares at $54.28 ($62,802)
- 4 Open-market sale Chief Legal Officer sold 630 shares at $54.28 ($34,196)
- 4 Open-market sale President & CEO sold 2,207 shares at $54.28 ($119,796)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale President & CEO sold 6,666 shares at an average $46.69 ($311,214)
- 4 Planned sale Chief R&D Officer sold 1,721 shares at an average $33.52 ($57,693)
- 4 Planned sale President & CEO sold 11,832 shares at an average $36.42 ($430,959)
- 4 Planned sale Chief R&D Officer sold 485 shares at $30.10 ($14,599)
- 4 Planned sale President & CEO sold 1,500 shares at $30.16 ($45,240)
- 4 Open-market sale Chief R&D Officer sold 725 shares at $26.59 ($19,278)
- 4 Open-market sale Chief Legal Officer sold 676 shares at $26.59 ($17,975)
- 4 Open-market sale President & CEO sold 1,573 shares at $26.59 ($41,826)
- 4 Open-market sale Chief R&D Officer sold 10,712 shares at $0.67 ($7,177)
- 4 Open-market sale Chief Legal Officer sold 9,996 shares at $0.67 ($6,697)
- 4 Open-market sale President & CEO sold 23,208 shares at $0.67 ($15,549)
- 4 Open-market sale Chief R&D Officer sold 10,300 shares at $1.01 ($10,403)
Page 2 of 49 · 968 filings